MiMedx CEO and Former COO sentenced for committing securities fraud

0
MiMedx CEO and Former COO sentenced for committing securities fraud
mohamed_hassan / Pixabay

Elliott Management stepped up its campaign against Altran Technologies’ sale to Capgemini last week, publishing a presentation detailing its position. Although the activist agrees that a deal makes sense, it argued the takeover price of 14 euros per share “neither reflects Altran’s intrinsic fair value, nor [is] an adequate premium for control.” Elliott said Altran shareholders could miss out on “significant value creation” as a result.

Elliott’s letter comes shortly after Capgemini CEO Paul Hermelin told Reuters he will not increase his offer and expressed confidence he would get 50.1% of shareholders behind the deal at the current price. “We saw things we liked and others we liked less,” Hermelin said, after seeing Altran’s books.

Get Our Activist Investing Case Study!

Get the entire 10-part series on our in-depth study on activist investing in PDF. Save it to your desktop, read it on your tablet, or print it out to read anywhere! Sign up below!